Nicox: Nicox Announces Scientific Presentation and Conference Attendance in H1 2025

Press Release Nicox Announces Scientific Presentation and Conference Attendance in H1 2025January 28, 2025 - release at 7:30 am CETSophia Antipolis, FranceNicox SA (PARIS:FR, ALCOX)), an international ophthalmology company, today announced a presentation at the upcoming American Glaucoma Society (AGS) Annual Meeting 2025 and participation in a number of key ophthalmology and financial conferences in the first half of 2025. Presentation of additional analysis of the NCX 470 Mont Blanc Phase 3 Clinical trial AGS 2025 Annual Meeting - February 26 to March 2, 2025, Washington, U.S. Poster Title: Diurnal Intraocular Pressure Control Responder Analysis with NCX 470 Versus Latanoprost in the Phase 3 MONT BLANC TrialType: Poster Presentation Session Date: Saturday March 1, 2025 from 7:00 am to 8:00 am (local time). Presenter: Dr. Robert Fechtner, Chair of the Department of Ophthalmology at SUNY Upstate Medical University in Syracuse, NY Upcoming Conference AttendanceAllinvest securities Biomed Forum - February 4, 2025 - Paris, France Investor Access - April 1-2, 2025 - Paris, France Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting - May 4-8, 2025 - Salt Lake City, Utah, U.S.BIO International Convention - June 16-19, 2025 - Boston, MA, U.S. Full story available on Benzinga.com